The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival.
A. Le Cesne
Consultant or Advisory Role - Novartis; PharmaMar
Honoraria - Novartis; Pfizer; PharmaMar
I. L. Ray-Coquard
Consultant or Advisory Role - Novartis; PharmaMar; Roche
Honoraria - Novartis; PharmaMar; Roche
B. Bui Nguyen
No relevant relationships to disclose
A. Adenis
No relevant relationships to disclose
M. Rios
No relevant relationships to disclose
F. Bertucci
No relevant relationships to disclose
F. Duffaud
No relevant relationships to disclose
D. Cupissol
No relevant relationships to disclose
C. Chevreau
No relevant relationships to disclose
E. Bompas
No relevant relationships to disclose
A. Cioffi
No relevant relationships to disclose
S. Chabaud
No relevant relationships to disclose
D. Perol
No relevant relationships to disclose
J. Blay
Consultant or Advisory Role - GlaxoSmithKline; Novartis; PharmaMar; Roche
Honoraria - Bayer; Novartis; PharmaMar; Roche